129 related articles for article (PubMed ID: 21508402)
1. Prognostic value of persistent peripheral blood and bone marrow lymphoblasts on day 15 of therapy in childhood acute lymphoblastic leukemia as detected by flow cytometry.
Jaworska-Posadzy A; Styczynski J; Kubicka M; Debski R; Rafinska-Kurylo B; Kolodziej B; Pogorzala M; Wysocki M
Anticancer Res; 2011 Apr; 31(4):1453-7. PubMed ID: 21508402
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.
Rivera GK; Zhou Y; Hancock ML; Gajjar A; Rubnitz J; Ribeiro RC; Sandlund JT; Hudson M; Relling M; Evans WE; Pui CH
Cancer; 2005 Jan; 103(2):368-76. PubMed ID: 15599932
[TBL] [Abstract][Full Text] [Related]
4. Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia.
Sandlund JT; Harrison PL; Rivera G; Behm FG; Head D; Boyett J; Rubnitz JE; Gajjar A; Raimondi S; Ribeiro R; Hudson M; Relling M; Evans W; Pui CH
Blood; 2002 Jul; 100(1):43-7. PubMed ID: 12070006
[TBL] [Abstract][Full Text] [Related]
5. Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction.
Ratei R; Basso G; Dworzak M; Gaipa G; Veltroni M; Rhein P; Biondi A; Schrappe M; Ludwig WD; Karawajew L;
Leukemia; 2009 Mar; 23(3):528-34. PubMed ID: 19020543
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of early treatment response in children with acute lymphoblastic leukemia: a single institution experience in Shanghai, China.
Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Chen J
Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jan; 11(1):5-9. PubMed ID: 19149913
[TBL] [Abstract][Full Text] [Related]
7. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Münster Relapse Study Group.
Bührer C; Hartmann R; Fengler R; Rath B; Schrappe M; Janka-Schaub G; Henze G
J Clin Oncol; 1996 Oct; 14(10):2812-7. PubMed ID: 8874343
[TBL] [Abstract][Full Text] [Related]
8. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
Björklund E; Mazur J; Söderhäll S; Porwit-MacDonald A
Leukemia; 2003 Jan; 17(1):138-48. PubMed ID: 12529671
[TBL] [Abstract][Full Text] [Related]
10. Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.
Uckun FM; Stork L; Seibel N; Sarquis M; Bedros C; Sather H; Sensel M; Reaman GH; Gaynon PS
Clin Cancer Res; 2000 Aug; 6(8):3123-30. PubMed ID: 10955793
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
[TBL] [Abstract][Full Text] [Related]
13. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
[TBL] [Abstract][Full Text] [Related]
14. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
15. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia.
Coustan-Smith E; Behm FG; Sanchez J; Boyett JM; Hancock ML; Raimondi SC; Rubnitz JE; Rivera GK; Sandlund JT; Pui CH; Campana D
Lancet; 1998 Feb; 351(9102):550-4. PubMed ID: 9492773
[TBL] [Abstract][Full Text] [Related]
16. Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis.
Ruggeri A; Michel G; Dalle JH; Caniglia M; Locatelli F; Campos A; de Heredia CD; Mohty M; Hurtado JM; Bierings M; Bittencourt H; Mauad M; Purtill D; Cunha R; Kabbara N; Gluckman E; Labopin M; Peters C; Rocha V
Leukemia; 2012 Dec; 26(12):2455-61. PubMed ID: 22555150
[TBL] [Abstract][Full Text] [Related]
17. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of flow cytometric minimal residual disease analysis in childhood acute lymphoblastic leukaemia at the end of remission induction therapy: results from a single UK centre.
Motwani J; Jesson J; Sturch E; Jones S; Eyre L; Short P; Davies P; Williams MD; Darbyshire PJ; Hill FG; Lawson S
Br J Haematol; 2009 Jan; 144(1):133-5. PubMed ID: 19016737
[No Abstract] [Full Text] [Related]
19. Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity.
Cortes J; Fayad L; O'Brien S; Keating M; Kantarjian H
Clin Cancer Res; 1999 Sep; 5(9):2491-7. PubMed ID: 10499624
[TBL] [Abstract][Full Text] [Related]
20. Day 22 of induction therapy is important for minimal residual disease assessment by flow cytometry in childhood acute lymphoblastic leukemia.
Xu XJ; Tang YM; Shen HQ; Song H; Yang SL; Shi SW; Xu WQ
Leuk Res; 2012 Aug; 36(8):1022-7. PubMed ID: 22483330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]